Parabilis Medicines
Series FParabilis Medicines is a privately held company based in United States, founded in 2016. The latest disclosed round is Series F ($305m), dated Jan 08, 2026. Institutional investors on record include General Catalyst.
United States · EST 2016
What is Parabilis Medicines?
Parabilis Medicines is a privately held company based in United States, founded in 2016. The latest disclosed round is Series F ($305m), dated Jan 08, 2026. Institutional investors on record include General Catalyst. Developer of peptide therapeutics for the treatment of severe diseases. CrackTheDeck lists dated rounds and linked fund profiles so founders can see who is already on the cap table before a pitch. Round sizes are shown only when disclosed. Empty fields mean the figure was not in those records. Open a fund name to read that firm's thesis, reported AUM, and recent dated deals. This page is compiled from financings linked to catalog funds. It is not a complete cap table. Founders use this card to check the latest disclosed round, amount, and syndicate before a meeting.
Which funds backed Parabilis Medicines?
Who invested in Parabilis Medicines?
Funds on the dated round table. Open a name to read the fund card.
| Investor | Round | Amount | Date |
|---|---|---|---|
| General Catalyst | Series F | $305m | Jan 08, 2026 |
What do founders ask about Parabilis Medicines?
What is Parabilis Medicines?
Parabilis Medicines is a privately held company based in United States, founded in 2016. The latest disclosed round is Series F ($305m), dated Jan 08, 2026. Institutional investors on record include General Catalyst. Developer of peptide therapeutics for the treatment of severe diseases. CrackTheDeck lists dated rounds and linked fund profiles so founders can see who is already on the cap table before a pitch. Round sizes are shown only when disclosed. Empty fields mean the figure was not in those records. Open a fund name to read that firm's thesis, reported AUM, and recent dated deals. This page is compiled from financings linked to catalog funds. It is not a complete cap table. Founders use this card to check the latest disclosed round, amount, and syndicate before a meeting.
What was Parabilis Medicines's last funding round?
Parabilis Medicines's latest disclosed round is Series F at $305m (Jan 08, 2026).
Who invested in Parabilis Medicines?
Parabilis Medicines has 1 institutional investors on this page, including General Catalyst.
How does CrackTheDeck cover Parabilis Medicines?
This startup card lists dated rounds and linked fund profiles so founders can see who is already in the cap table before a pitch.
How is this page compiled?
Round, amount, and investor names on the Parabilis Medicines card come from dated financings linked to fund profiles in CrackTheDeck. Empty fields mean the figure was not in those records. Updated Aug 2026.